Therapeutic Effects of Mesenchymal Stem Cells Expressing Erythropoietin
on Cancer-Related Anemia in Mice Model

Estiri, Mohammad; Estiri, Bahareh; Fallah, Asghar; Aghazadeh, Marziyeh; Sedaqati, Amir; Abdollahi, Abbas; Rabienia, Mahsa; Mortazavidehkordi, Nahid; Farjadfar, Akbar

doi:10.2174/1566523222666220405134136

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В настоящее время доступны различные препараты рекомбинантных ЭПО короткого и длительного действия: r-HuEPOα, r-HuEPOβ и дарбопоэтин α. Рекомбинантные ЭПО являются биологически и фармакологически активными при введении внутривенно, внутрибрюшинно, но особенно подкожно. Стандартный терапевтический режим составляет 150 МЕ/кг 3 раза в неделю для r-HuEPOα, или 40 000 МЕ один раз в неделю для r-HuEPOα [23][24][25][26][27][28][29][30].…”

Section: Introductionunclassified

Treatment of anemic syndrome in patients receiving surgical and chemotherapeutic treatment for breast and colorectal cancer

Khagazheeva,

Snegovoy,

Blindar

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Anemia syndrome is a common disease that reduces the quality and life expectancy of cancer patients. Prevention, timely diagnosis and effective treatment of anemia are statistically significantly associated with a favorable clinical outcome of the treatment of patients, and also contributes to better tolerability of anticancer therapy.Aim. Evaluation of the effectiveness of oral iron preparations and parenteral use of erythropoietin-alpha in patients with breast cancer and colorectal cancer, iron deficiency anemia or severe iron deficiency, immediate and long-term results of treatment, as well as the quality of life of patients with breast cancer and colorectal cancer.Materials and methods. A retrospective analysis of the material from the Blokhin National Medical Research Center of Oncology, involved 133 patients (validation group 68 people, control group – 65 people), patients with breast cancer or colorectal cancer, suffering from anemia. Depending on the form of anemia, patients were prescribed therapy – oral iron preparations with epoetin alfa in combination or in monotherapy. The effectiveness of therapy was assessed by the rate of blood hemoglobin. Analysis and statistical processing of results using IBM SPSS Statistics 26.0. Survival analysis was carried out using the Kaplan- Meier method. Descriptive statistics methods are used to analyze socio-demographic and traditional patients.Results. With a median follow-up of 61.2 months, the exclusion groups did not have significant differences in overall survival (p > 0.05). However, the group of patients with IDA who received therapy to correct the anemic syndrome and the group with FDA without adequate therapy had a greater significance in terms of 5-year OS (93.5 and 69.6%, respectively; p = 0.02). There were also no significant values for the 5-year DFS indicator (p > 0.05). However, the groups of patients with IDA who received and did not receive therapy to correct anemia probably made a big difference in terms of 5-year DFS (90.3 and 63.9%, respectively; p = 0.025). The group of patients with IDA treated with anemia to correct anemic syndrome clearly differed from the group of patients with FAD without therapy to correct anemia in terms of 5-year OS (90.3 and 43.6%, respectively; p < 0.001).Conclusions. Carrying out antianemic therapy can significantly increase the 5-year relapse-free survival in patients with iron deficiency anemia (90.3 and 63.9%, with and without therapy, respectively; p = 0.025).

show abstract